About
Technology
Issues
FAQ
Links
Official Page
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.